Cargando…

CD26 is a potential therapeutic target by humanized monoclonal antibody for the treatment of multiple myeloma

CD26, a 110-kDa transmembrane glycoprotein that is expressed on several tumor cells including malignant lymphoma, has been implicated in tumorigenesis: however, little is known regarding its role in multiple myeloma (MM). Recently, we identified CD26 expression on human osteoclasts (OCs) and demonst...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nishida, Hiroko, Hayashi, Mutsumi, Morimoto, Chikao, Sakamoto, Michiie, Yamada, Taketo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6197267/ https://www.ncbi.nlm.nih.gov/pubmed/30348967 http://dx.doi.org/10.1038/s41408-018-0127-y

Ejemplares similares

A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition
por: Hayashi, Mutsumi, et al.
Publicado: (2016)

Novel Antibody-Drug Conjugate with Anti-CD26 Humanized Monoclonal Antibody and Transcription Factor IIH (TFIIH) Inhibitor, Triptolide, Inhibits Tumor Growth via Impairing mRNA Synthesis
por: Hayashi, Mutsumi, et al.
Publicado: (2019)

Localization of CD26/DPPIV in nucleus and its nuclear translocation enhanced by anti-CD26 monoclonal antibody with anti-tumor effect
por: Yamada, Kohji, et al.
Publicado: (2009)

Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription
por: Yamada, Kohji, et al.
Publicado: (2013)

P1369: HDAC INHIBITION INVOLVES CD26 EXPRESSION ON MULTIPLE MYELOMA CELLS VIA THE C-MYC/SP1-MEDIATED PROMOTER ACTIVATION AND OVERCOMES THERAPEUTIC RESISTANCE BY HUMANIZED ANTIBODY
por: Nishida, Hiroko, et al.
Publicado: (2023)

Monoclonal Antibody Therapies in Multiple Myeloma: A Challenge to Develop Novel Targets
por: Nishida, Hiroko, et al.
Publicado: (2019)

Establishment of monoclonal anti-human CD26 antibodies suitable for immunostaining of formalin-fixed tissue
por: Hatano, Ryo, et al.
Publicado: (2014)

Development of novel monoclonal antibodies with specific binding affinity for denatured human CD26 in formalin-fixed paraffin-embedded and decalcified specimens
por: Hatano, Ryo, et al.
Publicado: (2019)

First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers
por: Angevin, Eric, et al.
Publicado: (2017)

Clinical Significance of Soluble CD26 in Malignant Pleural Mesothelioma
por: Fujimoto, Nobukazu, et al.
Publicado: (2014)

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma
por: Nakagawa, Kazuhiko, et al.
Publicado: (2021)

CD26/Dipeptidyl Peptidase IV and Its Multiple Biological Functions
por: Pan, Kelsey, et al.
Publicado: (2021)

Anti CD38 monoclonal antibodies for multiple myeloma treatment
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Development of a Novel CD26-Targeted Chimeric Antigen Receptor T-Cell Therapy for CD26-Expressing T-Cell Malignancies
por: Kobayashi, Eiji, et al.
Publicado: (2023)

Regulation of CD38 on Multiple Myeloma and NK Cells by Monoclonal Antibodies
por: Wu, Hao-Tian, et al.
Publicado: (2022)

Therapeutic Monoclonal Antibodies and Antibody Products: Current Practices and Development in Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2019)

Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody
por: Kaneko, Yutaro, et al.
Publicado: (2021)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Current and Emerging Therapy for Malignant Pleural Mesothelioma: Focus on CD26/Dipeptidyl Peptidase IV as a Therapeutic Target
por: Doonan, Bently P., et al.
Publicado: (2017)

Macrophage migration inhibitory factor‐CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells
por: Imaoka, Masako, et al.
Publicado: (2019)

Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update
por: Abramson, Hanley N.
Publicado: (2018)

Bone-targeted agents in multiple myeloma
por: Nishida, Hiroko
Publicado: (2018)

Cd26/Dipeptidyl Peptidase IV in Context: The Different Roles of a Multifunctional Ectoenzyme in Malignant Transformation
por: Iwata, Satoshi, et al.
Publicado: (1999)

Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma
por: Sanchez, Larysa, et al.
Publicado: (2016)

WDR26 and MTF2 are therapeutic targets in multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2021)

Elotuzumab: The First Monoclonal Antibody for the Treatment of Multiple Myeloma
por: Fancher,(1,2), Karen M., et al.
Publicado: (2016)

Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma
por: Dalla Palma, Benedetta, et al.
Publicado: (2020)

Monoclonal Antibodies: The Greatest Resource to Treat Multiple Myeloma
por: De Luca, Fabiola, et al.
Publicado: (2023)

CD9 Negatively Regulates CD26 Expression and Inhibits CD26-Mediated Enhancement of Invasive Potential of Malignant Mesothelioma Cells
por: Okamoto, Toshihiro, et al.
Publicado: (2014)

Establishment of anti-mesothelioma monoclonal antibodies
por: Mizutani, Natsuko, et al.
Publicado: (2016)

DPP8 is a novel therapeutic target for multiple myeloma
por: Sato, Tsutomu, et al.
Publicado: (2019)

T-cell activation via CD26 and caveolin-1 in rheumatoid synovium
por: Ohnuma, Kei, et al.
Publicado: (2006)

Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives
por: Lonial, S, et al.
Publicado: (2016)

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma
por: Cho, Shih-Feng, et al.
Publicado: (2017)

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
por: D’Agostino, Mattia, et al.
Publicado: (2020)

Monoclonal Antibodies: Leading Actors in the Relapsed/Refractory Multiple Myeloma Treatment
por: Morè, Sonia, et al.
Publicado: (2020)

Targeting Human β-Microglobulin with Monoclonal Antibodies in Multiple Myeloma - A Potential in Treatment
por: Zhang, Mingjun, et al.
Publicado: (2016)

CD9 expression as a favorable prognostic marker for patients with malignant mesothelioma
por: AMATYA, VISHWA JEET, et al.
Publicado: (2012)

Sequential CD38 monoclonal antibody retreatment leads to deep remission in a patient with relapsed/refractory multiple myeloma
por: Steinhardt, Maximilian Johannes, et al.
Publicado: (2020)

Perspectives for the Development of CD38-Specific Heavy Chain Antibodies as Therapeutics for Multiple Myeloma
por: Bannas, Peter, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_h5b6hn3e3svgrj65pfj47t05mr